基于因子分析的生物医药行业上市公司业绩评价

The Performance Evaluation of Biological Medical Listed Companies Based on Factor Analysis

以沪深A股生物医药行业69家上市公司为研究对象,利用其2008年-2012年财务数据,运用因子分析方法对该类公司经营业绩进行综合评价,研究结果表明：偿债能力对该类上市公司业绩影响最大,是决定公司综合业绩水平的关键因素;盈利能力则是影响公司业绩的第二大因素,发展能力对公司业绩影响较小,但引领作用比较显著;整体上,公司偿债、盈利、运营和获利能力不高,且发展不均衡,公司业绩差异明显;整个行业公司经营业绩水平的层次性较为明显,公司综合业绩水平较低。

Based on the financial data of China＇s 69 listed biological medical companies from 2008 to 2012, the paper comprehensively evaluates their operating performance with factor analysis method. The results show： solvency has the greatest impact on the performance of those listed companies, it is also the key factor to determine the level of the company＇s comprehensive performance, profitability is the second major factor affecting the performance of the company,the development capacity has smaller impact on the performance of the company, but the leading role is significant; on the whole, corporate solvency, profit, operation and profitability are not high, and the development is not balanced, the performances of the companies different significantly. the level of the business performance of the whole industry is obvious, the comprehensive performance level is relatively low.